Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lopinavir.

M Hurst1, D Faulds

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|January 11, 2001
PubMed
Summary
This summary is machine-generated.

Lopinavir/ritonavir combination therapy effectively suppresses HIV replication in both treatment-naive and experienced patients. This protease inhibitor regimen demonstrates superior efficacy compared to nelfinavir in certain patient groups.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study.

BMC cancer·2022
Same author

Bronchiectasis is associated with delayed diagnosis and adverse outcomes in the New Zealand Common Variable Immunodeficiency Disorders cohort study.

Clinical and experimental immunology·2021
Same author

Comparison of 3-day and 7-day recall periods for food consumption reference values in foodborne disease outbreak investigations.

Epidemiology and infection·2019
Same author

Evaluation of the QBC Star centrifugal three-part differential haematology system.

British journal of biomedical science·2013
Same author

Incidence of hypoglycemia with tight glycemic control protocols: a comparative study.

Diabetes technology & therapeutics·2010
Same author

Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Virology
  • Pharmacology
  • Infectious Diseases

Background:

  • Lopinavir is a highly specific HIV-1 protease inhibitor.
  • Ritonavir significantly enhances lopinavir plasma concentrations by inhibiting its metabolism.
  • The combination of lopinavir and ritonavir (lopinavir/ritonavir) aims to improve antiviral efficacy.

Purpose of the Study:

  • To evaluate the efficacy and safety of lopinavir/ritonavir in suppressing HIV replication.
  • To compare lopinavir/ritonavir with nelfinavir in antiretroviral-naive patients.
  • To assess lopinavir/ritonavir in protease inhibitor-experienced patients and pediatric populations.

Main Methods:

  • Clinical trials involving antiretroviral-naive and experienced adult and pediatric patients.
  • Administration of lopinavir/ritonavir at various doses and durations, often in combination with nucleoside reverse transcriptase inhibitors (NRTIs) and/or non-nucleoside reverse transcriptase inhibitors.

Related Experiment Videos

  • Comparison of viral suppression rates between lopinavir/ritonavir and nelfinavir regimens.

    • Main Results:

    • Lopinavir/ritonavir demonstrated significantly greater HIV replication suppression than nelfinavir in antiretroviral-naive patients.
    • Most protease inhibitor-experienced patients achieved viral suppression with lopinavir/ritonavir-based regimens.
    • The majority of pediatric patients (6 months to 12 years) also showed suppressed viral replication with lopinavir/ritonavir.

    Conclusions:

    • Lopinavir/ritonavir is an effective treatment for suppressing HIV replication in diverse patient populations.
    • The combination therapy offers a favorable efficacy profile, particularly in comparison to nelfinavir.
    • Common adverse effects include gastrointestinal issues and asthenia, with potential for elevated lipids and hepatic enzymes.